The results showed that patients whose driver oncogenes were specifically targeted lived, on average, a year longer than those who received standard chemotherapy.

结果显示其致癌基因因子得到针对性地治疗的患者存活了，平均来说他们比那些接受标准化疗的患者多活一年。